Study of inhibitor development in hemophilia A patients using Coageight
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study looks at how often people with hemophilia A develop inhibitors (antibodies that block the effectiveness of factor VIII) after using Coageight, a factor VIII replacement therapy. It may help understand the safety of this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be male and 2 years or older
- Have hemophilia A
- Have had at least 50 exposure days to any factor VIII product
- Have used Coageight for at least 10 days in the past 12 months
- Have no other bleeding disorders, hepatitis B or C, or current participation in another study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study watches how well damoctocog alfa pegol (a medicine to help blood clot) works in children with hemophilia A. It is for kids ages 7 to 12 who have used factor VIII before and do not have inhibitors (antibodies that stop the medicine from working).
This trial studies a treatment approach for people with hemophilia A who develop antibodies (inhibitors) that block clotting factor FVIII. It may help those whose usual FVIII therapy is not working because of these inhibitors.
This study tests how well a new factor VIII medicine, efanesoctocog alfa, protects your joints over time. It's for people with moderate or severe hemophilia A who are just starting this treatment.
This study looks at how safe and effective Octocog alfa (a Factor VIII medicine) is for treating sudden bleeds in adults with severe hemophilia A in India. It is for people who already have experience with Factor VIII products and are not on regular preventive treatment.
This study checks how well efanesoctocog alfa (a preventive factor VIII treatment) protects your joints over time in people with hemophilia A. It involves regular checkups, joint assessments, and tracking of any bleeding episodes.
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.